Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: MRTX849 Monotherapy; Drug: MRTX849 in Combination with Pembrolizumab
Sponsor: Mirati Therapeutics Inc.
Recruiting
Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: MRTX849 Monotherapy; Drug: MRTX849 in Combination with Pembrolizumab
Sponsor: Mirati Therapeutics Inc.
Recruiting